Search

Displaying results 7471 - 7480 of 7673 in total
  1. Drug

    Taurochenodeoxycholic acid

    go.drugbank.com/drugs/DB08833
    Experimental

    Taurochenodeoxycholic acid is an experimental drug that is normally produced in the liver. Its physiologic function is to emulsify lipids such as cholesterol in the bile.

  2. Drug

    Tyramine

    go.drugbank.com/drugs/DB08841
    InvestigationalNutraceutical

    An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects.

  3. Drug

    Paquinimod

    go.drugbank.com/drugs/DB13118
    Investigational

    Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease.

  4. Drug

    Mito-4509

    go.drugbank.com/drugs/DB05846
    Experimental

    Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways. It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.

  5. Drug

    UC-781

    go.drugbank.com/drugs/DB05871
    Investigational

    UC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.

  6. Drug

    VX-148

    go.drugbank.com/drugs/DB06103
    Experimental

    VX-148 is a second-generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH). The IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes....

  7. Drug

    NB-001

    go.drugbank.com/drugs/DB12716
    Investigational

    NB-001 has been investigated for the treatment of Recurrent Herpes Labialis.

  8. Drug

    Ticalopride

    go.drugbank.com/drugs/DB06422
    Experimental

  9. Drug

    XL999

    go.drugbank.com/drugs/DB05014
    Investigational

    XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic prop...

  10. Drug

    AEOL-10150

    go.drugbank.com/drugs/DB05874
    Experimental

    AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.